Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab + cyclophosphamide + doxorubicin hydrochloride + vincristine sulfate + prednisone + roflumilast
- Development stage
- Phase 1
- Lead developer
- UT Health San Antonio
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This investigational combination therapy, developed by The University of Texas Health Science Center at San Antonio, integrates the standard-of-care R-CHOP chemoimmunotherapy regimen with roflumilast, an oral phosphodiesterase 4 (PDE4) inhibitor. R-CHOP consists of rituximab (a CD20-targeting monoclonal antibody), cyclophosphamide (an alkylating agent), doxorubicin hydrochloride (an anthracycline), vincristine sulfate (a vinca alkaloid), and prednisone (a corticosteroid). The addition of roflumilast is intended to enhance therapeutic efficacy in high-risk diffuse large B-cell lymphoma (DLBCL) by inhibiting PDE4, which suppresses B-cell receptor signaling, PI3K/AKT activity, and angiogenesis within the lymphoma microenvironment. This regimen has been evaluated in Phase I and Phase II clinical trials for treatment-naïve patients with moderate-to-high risk DLBCL.
- Other names
- R-CHOP-RoflumilastRoflumilast with R-CHOP
02
Targets
CD20 (B-lymphocyte antigen CD20)DNATOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)PDE4 (Phosphodiesterase 4A1)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on rituximab + cyclophosphamide + doxorubicin hydrochloride + vincristine sulfate + prednisone + roflumilast.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab + cyclophosphamide + doxorubicin hydrochloride + vincristine sulfate + prednisone + roflumilast.